Cyclopentolate
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Cyclopentolate: From Ophthalmic Cycloplegia to Cauda Equina Syndrome
One-Sentence Summary
Cyclopentolate is a short-acting antimuscarinic agent used clinically as an ophthalmic mydriatic/cycloplegic (pupil dilation and ciliary muscle paralysis for eye exams). The TxGNN model assigns a high prediction score (99.54%) linking it to Cauda Equina Syndrome, but currently 0 clinical trials and 0 publications support this association, and the evidence pack’s own mechanistic review flags this specific link as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ophthalmic cycloplegia/mydriasis (based on known pharmacological class; not recorded in the current regulatory data extract) |
| Predicted New Indication | Cauda Equina Syndrome |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacological class information, cyclopentolate is a short-acting antimuscarinic that blocks muscarinic (M) receptors in the eye’s sphincter and ciliary muscles, producing pupil dilation and temporary loss of accommodation. It is used exclusively as a topical ophthalmic agent for diagnostic and pre/post-operative purposes, not as a systemic therapeutic.
Cauda equina syndrome, however, is a surgical emergency caused by mechanical compression of the lumbosacral nerve roots — a structural/neurological problem with no established connection to muscarinic receptor blockade. The evidence pack’s own rationale is explicit on this point: the high TxGNN score most likely reflects an indirect knowledge-graph association (e.g., shared “nervous system” node clustering) rather than a real pharmacological pathway, and no causal mechanism can be identified.
Notably, the pack’s two lower-ranked candidates for this drug — neurogenic bladder and irritable bowel syndrome — have a stronger mechanistic rationale, since antimuscarinics are an established drug class for both conditions (via bladder detrusor M3 or gut smooth-muscle M3 blockade). Cauda equina syndrome stands out as the weakest-supported of the three predictions and should not be prioritized over them.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Cyclopentolate is currently not marketed, with no registration records available in the evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a model-only prediction (L5, decision stage S0) with no clinical trials, no literature, and — per the evidence pack’s own mechanistic analysis — no plausible causal pathway between antimuscarinic action and cauda equina syndrome’s compressive pathophysiology. The drug is also not currently marketed, so there is no existing indication base to build on.
To proceed, the following is needed:
- TFDA label warnings/contraindications (blocking data gap — required before any safety pre-assessment)
- Confirmed mechanism of action from DrugBank or primary literature
- Preclinical or mechanistic studies establishing a credible biological rationale before further evaluation
- If pursuing repurposing for this drug, re-evaluate the higher-plausibility candidates (neurogenic bladder, irritable bowel syndrome) instead of this top-ranked but mechanistically weak candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.